Dyne Therapeutics (DYN) Suspends ATM Offering

On January 4, 2024, Dyne Therapeutics Inc. (NASDAQ: DYN) notified Jefferies LLC (“Jefferies”) that it was suspending and terminating the prospectus, dated November 17, 2021 (the “ATM Prospectus”), related to the sales agreement (the “Sales Agreement”) that the Company entered into with Jefferies on November 4, 2021 and pursuant to which the Company may offer and sell shares of its common stock, $0.0001 par value per share (the “Common Stock”), from time to time through Jefferies, as agent, under an “at-the-market” offering program. The Company will not make any sales of its Common Stock pursuant to the Sales Agreement unless and until a new prospectus is filed. The Sales Agreement remains in full force and effect. As of January 4, 2024, the Company had issued and sold an aggregate of 7,943,148 shares of its Common Stock under its “at-the-market” offering program with Jefferies for aggregate gross sale proceeds of $92.2 million, before deducting sales commissions and offering expenses.

You May Also Be Interested In

• Healthcare Triangle, Inc (HCTI) files for 28M share offering by selling stockholders
• Niagen Bioscience files to sell up to $50M in common stock
• Enova adds Maria Veltre to board as two directors retire